Study guide

3.8 Feeding/Eating, Sleep-Wake, and Somatic Symptom Disorders

ANCC Psychiatric-Mental Health Nurse Practitioner PMHNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Scientific Foundation

1.1 Neuroanatomy and Brain Function 1.2 Neurotransmitters and Synaptic Transmission 1.3 Neurodevelopmental and Neuroendocrine Mechanisms 1.4 Psychbehavioral Genetics and Epigenetics 1.5 Psychoneuroimmunology and Inflammatory Pathways 1.6 Psychopathology and Diagnostic Foundations 1.7 Evidence-Based Practice and Research Methodologies 1.8 Lifespan Growth and Development Theories 1.9 Health Promotion and Disease Prevention

2 Chapter 2: Advanced Practice Skills

2.1 Comprehensive Psychiatric Interview and Health History 2.2 Mental Status Examination (MSE) Concepts and Clinical Application 2.3 Physical and Neurological Assessment in Psychiatry 2.4 Diagnostic Laboratory and Imaging Interpretation 2.5 Suicide Risk Assessment and Safety Formulation 2.6 Violence and Homicide Risk Assessment 2.7 Substance Use, Intoxication, and Withdrawal Assessment 2.8 Cultural Competence and Social Determinants of Mental Health 2.9 Therapeutic Alliance and Clinical Communication 2.10 Functional and Diagnostic Risk Stratification

3 Chapter 3: Diagnosis and Treatment

3.1 Neurodevelopmental and Schizophrenia Spectrum Disorders 3.2 Bipolar and Related Disorders 3.3 Depressive Disorders 3.4 Anxiety Disorders, OCD, and Trauma-Related Disorders 3.5 Substance-Related and Addictive Disorders 3.6 Neurocognitive Disorders 3.7 Personality Disorders 3.8 Feeding/Eating, Sleep-Wake, and Somatic Symptom Disorders 3.9 Psychopharmacology Foundations: Antipsychotics and Mood Stabilizers 3.10 Psychopharmacology Foundations: Antidepressants, Anxiolytics, and Stimulants

4 Chapter 4: Psychotherapy and Related Theories

4.1 Cognitive Behavioral Therapy (CBT) and Dialectical Behavior Therapy (DBT) 4.2 Psychodynamic and Psychoanalytic Theories 4.3 Humanistic, Person-Centered, and Motivational Interviewing 4.4 Family and Group Psychotherapy Modalities 4.5 Integrative and Complementary Mental Health Approaches

5 Chapter 5: Ethics, Legal Principles, and Cultural Care

5.1 Patient Autonomy, Informed Consent, and Capacity 5.2 Involuntary Commitment and Patient Rights 5.3 Confidentiality, HIPAA, and Duty to Protect 5.4 Professional Scope of Practice and Prescriptive Authority 5.5 Malpractice, Liability, and Risk Management 5.6 Health Policy, Advocacy, and Mental Health Parity 5.7 Quality Improvement, Patient Safety, and Interprofessional Collaboration 5.8 Telepsychiatry, Technology, and Ethical Care Delivery

3.8 Feeding/Eating, Sleep-Wake, and Somatic Symptom Disorders

Key Takeaways Explain This Topic AI

Anorexia Nervosa requires BMI < 18.5 kg/m² (Mild: 17-18.49; Moderate: 16-16.99; Severe: 15-15.99; Extreme: < 15 kg/m²), intense fear of weight gain, and body image distortion, carrying a 5-10% mortality rate per decade.

Refeeding Syndrome in severe malnutrition occurs upon carbohydrate reintroduction, causing an insulin surge that shifts phosphate, potassium, and magnesium intracellularly, resulting in severe hypophosphatemia (< 2.0 mg/dL), cardiac arrhythmias, and sudden cardiac death.

Bulimia Nervosa involves recurrent binge eating and inappropriate compensatory purging behaviors ≥ 1 time/week for 3 months at normal or elevated BMI; Fluoxetine 60 mg/day is the only FDA-approved medication.

Bupropion is strictly CONTRAINDICATED in Anorexia Nervosa and Bulimia Nervosa due to a 4-fold increase in seizure incidence (up to 18% in eating disorder clinical trials).

Cognitive Behavioral Therapy for Insomnia (CBT-I) is the gold-standard first-line treatment for Insomnia Disorder (symptoms ≥ 3 nights/week for ≥ 3 months), outperforming chronic hypnotic pharmacotherapy in long-term efficacy.

Last updated: July 2026

Feeding and Eating Disorders

Feeding and eating disorders are characterized by a persistent disturbance of eating or eating-related behavior that results in the altered consumption or absorption of food and significantly impairs physical health or psychosocial functioning.

1. Anorexia Nervosa (AN)

DSM-5-TR Diagnostic Criteria:

Restriction of energy intake relative to requirements, leading to a significantly low body weight in the context of age, sex, developmental trajectory, and physical health (defined as a BMI < 18.5 kg/m² in adults or BMI-for-age percentile < 5th percentile in children/adolescents).

Intense fear of gaining weight or of becoming fat, or persistent behavior that interferes with weight gain, even though at a significantly low weight.

Disturbance in the way in which one's body weight or shape is experienced, undue influence of body weight or shape on self-evaluation, or persistent lack of recognition of the seriousness of the current low body weight.

Subtypes:

Restricting Type: During the last 3 months, weight loss is accomplished primarily through dieting, fasting, and/or excessive exercise. No recurrent binge eating or purging.

Binge-Eating/Purging Type: During the last 3 months, the individual has engaged in recurrent episodes of binge eating or purging behavior (self-induced vomiting, misuse of laxatives, diuretics, or enemas).

BMI Severity Index (Adults): Mild (BMI ≥ 17 kg/m²), Moderate (BMI 16–16.99 kg/m²), Severe (BMI 15–15.99 kg/m²), Extreme (BMI < 15 kg/m²) .

Physical Exam Findings: Hypothermia (< 36°C / 96.8°F), sinus bradycardia (< 50 bpm), hypotension (< 90/60 mmHg), orthostatic BP drops, lanugo (fine, soft neonatal-type hair on trunk/extremities), dry skin, peripheral edema, salivary gland hypertrophy (parotid enlargement), amenorrhea (no longer a mandatory DSM-5-TR criterion, but common).

Laboratory & Electrocardiogram (ECG) Abnormalities: Leukopenia, anemia, thrombocytopenia, elevated BUN (dehydration), hypokalemia, hypomagnesemia, hyponatremia, hypoglycemia, elevated LFTs, decreased T3 (euthyroid sick syndrome), prolonged QTc interval , ST-segment depression, T-wave inversion, and U waves on ECG.

Indications for Immediate Medical Hospitalization:

  • Heart rate < 40 beats per minute
  • Blood pressure < 90/60 mmHg or severe orthostatic changes (HR increase > 20 bpm, BP drop > 10 mmHg)
  • Cardiac arrhythmias or prolonged QTc
  • Body temperature < 36°C (96.8°F)
  • Body weight < 75% of ideal body weight (BMI < 15 kg/m²)
  • Hypokalemia (< 3.0 mEq/L), hypophosphatemia, or severe electrolyte derangement
  • Intractable purging or refusal to eat
  • The Refeeding Syndrome Emergency

Refeeding Syndrome is a critical, life-threatening metabolic complication occurring when nutrition (oral, enteral, or parenteral) is reintroduced to a severely malnourished patient.

Pathophysiology: Malnourishment induces a catabolic state with depleted intracellular stores of phosphate, potassium, and magnesium. Reintroducing carbohydrates stimulates a rapid insulin surge . Insulin shifts glucose, phosphate, potassium, and magnesium from extracellular space into the cells to support glycolysis and protein synthesis.

Hallmark Laboratory Finding: Severe, precipitous HYPOPHOSPHATEMIA (along with hypokalemia and hypomagnesemia).

Clinical Manifestations: Cardiac dysrhythmias, acute heart failure, pulmonary edema, seizures, delirium, rhabdomyolysis, neuromuscular paralysis, and sudden cardiac death.

Prevention & PMHNP Management: Reintroduce calories slowly (10–15 kcal/kg/day), monitor serum electrolytes (phosphate, potassium, magnesium) daily, supplement electrolytes prior to and during refeeding, and restrict sodium and fluid intake initially.

Treatment Protocols for AN:

Psychotherapy: Family-Based Treatment (FBT / Maudsley Approach) is the gold-standard first-line treatment for adolescents, empowering parents to manage weight restoration. Enhanced Cognitive Behavioral Therapy (CBT-E) for adults.

Pharmacotherapy: No FDA-approved medications exist for AN core symptoms. Olanzapine (Zyprexa) (2.5–10 mg daily) is used off-label to promote weight gain, attenuate obsessive food-related anxiety, and reduce agitation.

CONTRAINDICATION WARNING: Bupropion (Wellbutrin) is strictly CONTRAINDICATED in Anorexia Nervosa and Bulimia Nervosa due to a high risk of drug-induced grand mal seizures.

2. Bulimia Nervosa (BN)

DSM-5-TR Diagnostic Criteria:

Recurrent episodes of binge eating (eating in a discrete period an amount of food definitely larger than most people would eat, with a sense of lack of control).

Recurrent inappropriate compensatory behaviors to prevent weight gain (self-induced vomiting, laxative, diuretic, or other medication misuse, fasting, or excessive exercise).

Both occur, on average, at least once a week for 3 months .

Self-evaluation is unduly influenced by body shape and weight.

Does not occur exclusively during episodes of Anorexia Nervosa (patients are typically at normal weight or overweight , BMI ≥ 18.5 kg/m²).

Physical Exam Signs:

Russell's Sign: Calluses or abrasions on the dorsal surface of the hand/knuckles from repeated contact with incisor teeth during self-induced vomiting.

Sialadenosis: Bilateral painless hypertrophy of the parotid salivary glands.

Dental Enamel Erosion: Loss of dental enamel on the lingual surfaces of anterior teeth from exposure to gastric acid.

Laboratory Profile: Hypokalemic, hypochloremic metabolic alkalosis (from loss of gastric HCl via vomiting). Note: Excessive laxative abuse leads to hypokalemic metabolic acidosis (loss of bicarbonate via stool).

Pharmacotherapy: Fluoxetine (Prozac) 60 mg daily is the ONLY FDA-approved medication for Bulimia Nervosa. Higher doses (60 mg) are required compared to depression dosing. Reduces bingeing and purging frequency.

3. Binge-Eating Disorder (BED)

Diagnostic Criteria: Recurrent episodes of binge eating occurring at least once a week for 3 months , associated with ≥3: eating much more rapidly than normal, eating until uncomfortably full, eating large amounts when not hungry, eating alone due to embarrassment, feeling disgusted/depressed/guilty afterward. NO regular use of inappropriate compensatory behaviors.

Treatment: CBT-E, Interpersonal Psychotherapy (IPT).

FDA-Approved Pharmacotherapy: Lisdexamfetamine (Vyvanse) (30–70 mg daily) is the only FDA-approved medication for moderate-to-severe BED. Off-label options: Topiramate, SSRIs.

  • Sleep-Wake Disorders
  • 1. Insomnia Disorder

DSM-5-TR Diagnostic Criteria: Predominant complaint of dissatisfaction with sleep quantity or quality, associated with difficulty initiating sleep, difficulty maintaining sleep, or early-morning awakening with inability to return to sleep. Causes clinically significant distress or impairment. Occurs at least 3 nights per week for at least 3 months , despite adequate opportunity for sleep.

Sleep Architecture: NREM Sleep (Stage N1 [light], Stage N2 [sleep spindles/K-complexes], Stage N3 [Slow-Wave/Delta sleep—restorative]), and REM Sleep (dreaming, muscle atonia). Aging reduces Stage N3 slow-wave sleep.

First-Line Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I) is the gold-standard first-line treatment, superior to medications long-term. Components include:

Stimulus Control: Bed is strictly for sleep and sex. If unable to sleep after 20 minutes, get out of bed and perform a quiet activity in dim light until sleepy.

Sleep Restriction Therapy: Limiting time in bed to actual sleep duration to increase sleep efficiency.

Sleep Hygiene: Avoiding caffeine/alcohol near bedtime, maintaining consistent wake times, eliminating screens/blue light.

Pharmacotherapy Guidelines:

Non-Benzodiazepine Hypnotics (Z-drugs): Zolpidem (Ambien), Eszopiclone (Lunesta), Zaleplon (Sonata). Act selectively on GABA-A alpha-1 subunit. Risk of complex sleep behaviors (sleep-walking, sleep-driving).

Dual Orexin Receptor Antagonists (DORAs): Suvorexant (Belsomra), Lemborexant (Dayvigo). Block wake-promoting orexin signaling.

Melatonin Receptor Agonists: Ramelteon (Rozerem) (MT1/MT2 agonist; no abuse potential).

Sedating Antidepressants: Doxepin low-dose (3–6 mg), Trazodone (25–100 mg), Mirtazapine (7.5–15 mg).

2. Obstructive Sleep Apnea (OSA) vs. Narcolepsy

OSA: Repetitive upper airway collapse during sleep. Diagnosed via Polysomnography showing Apnea-Hypopnea Index (AHI) ≥ 5 with daytime sleepiness. Treatment: Continuous Positive Airway Pressure (CPAP). Avoid CNS depressants and sedating medications.

Narcolepsy: Primary central sleepiness disorder caused by loss of hypothalamic hypocretin (orexin)-producing neurons .

Classic Tetrad: 1. Excessive Daytime Sleepiness (EDS); 2. Cataplexy (sudden loss of muscle tone triggered by strong emotions like laughter); 3. Sleep Paralysis; 4. Hypnagogic (falling asleep) or Hypnopompic (waking up) Hallucinations.

Treatment: Modafinil (Provigil) or Armodafinil (Nuvigil) for daytime sleepiness; Pitolisant (H3 antagonist) or Sodium Oxybate (Xyrem) (GABA-B agonist) for cataplexy.

Somatic Symptom and Related Disorders: Differential Matrix

Disorder Name Core Somatic Presentation Psychological & Behavioral Manifestations Unconscious vs. Conscious Motivation Secondary / External Gain

Somatic Symptom Disorder One or more distressing physical symptoms (e.g., pain, fatigue) Excessive thoughts, high health anxiety, disproportionate time/energy devoted to symptoms (> 6 months) Unconscious symptoms; genuine suffering Absent (Primary internal gain of expressing psychological distress somatically)

Illness Anxiety Disorder Somatic symptoms are absent or minimal Preoccupation with having or acquiring a serious medical illness; excessive health checking or avoidance (> 6 months) Unconscious anxiety; genuine fear of illness Absent

Conversion Disorder (FND) Altered voluntary motor or sensory function (e.g., blindness, paralysis, PNES) Clinical findings show incompatibility between symptom and recognized neuro-medical conditions Unconscious production; genuine neurological deficit Absent (Often preceded by acute stressor; La belle indifférence may occur)

Factitious Disorder Falsification of physical/psychological signs or induction of injury/disease Presents self (or another—Factitious Disorder Imposed on Another / By Proxy) as ill, impaired, or injured Conscious production of fake symptoms; Unconscious motivation (assuming sick role) Absent (Driven strictly by internal need for sick role/attention)

Malingering (Not a DSM-5-TR Psychiatric Disorder) Intentional fabrication or gross exaggeration of physical or psychological symptoms Clear external incentives present Conscious production of symptoms; Conscious motivation PRESENT (Financial gain, disability insurance, avoiding criminal prosecution, obtaining opioids)

Clinical Management Principles for Somatic Disorders

Establish a Single Point of Care: Schedule regular, brief, structured appointments with one primary PMHNP/PCP (e.g., every 4–6 weeks) regardless of symptom severity.

Validate Distress Without Reinforcing Sickness: Acknowledge that the patient's physical pain/distress is real ("I can see how much pain this causes you") while avoiding unnecessary diagnostic workups, invasive procedures, or specialist referrals.

Psychotherapy: Cognitive Behavioral Therapy (CBT) focused on shifting focus from symptoms to coping mechanisms and stress reduction.

Loading diagram...